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One of the primary aims of the genetic coun-
selor is the reduction in the number of children 
born with either lethal disorders or severe CNS 
dysfunction (eg. mongolism and midline neural de-
fects). Generally, this goal is accomplished in one 
of four major ways: 
1) Where a child's disorder is known to be 
inherited in a Mendelian fashion, by clearly 
stating the recurrence risk of 1 : 2 or 1 : 4, 
which is often a deterrent to a parent pair 
to plan further pregnancies; 
2) By counseling based on empirically estab-
lished recurrence risk statistics; 
3) Where the risk is high, by determining the 
status of the fetus at 14-16 weeks by 
aspiration and study of amniotic fluid (am-
niocentesis,)-when the mother is over 
age 40, or has had a previous child with 
mongolism, a sex-linked disorder, or one of 
so~ fifty metabolic disorders which may 
be diagnosed by amniotic fluid study, the 
pregnancy can be terminated before twenty 
weeks gestation if one of the disorders is 
detected; 
4) By ascertainment of parent pairs where 
both are carriers of an autosomal recessive 
disorder before birth of an involved child 
so that parents may be advised of the high 
risk of occurrence of this disorder in their 
offspring and also be advised of the avail-
ability or nonavailability of intrauterine 
diagnosis by amniocentesis. 
At present, two carrier detection programs (for 
sickle cell anemia and Tay-Sachs disease) have been 
developed because the following necessary criteria 
have been met: 
1) The carrier test is rapid, accurate, and in-
expensive within a defined population; 
2) The frequency of the carrier state is high 
enough within a defined population to justify the 
cost of testing; 
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3) The disorder is a serious health hazard for 
which there is no definitive cure. 
One other disorder, cystic fibrosis (rare in the 
Black race) meets criteria 2 and 3 but unfortunately, 
not 1. As soon as an effective carrier test for this 
disease is developed, however, it will be offered 
to whites just as today, blacks have available sickle 
cell testing and Jews, a Tay-Sachs screening test. 
The major purpose of this article is to briefly 
summarize the concept of a Tay-Sachs carrier de-
tection program and to share our experiences in 
Virginia. This disease, first described by Drs. Tay 
and Sachs in the 1880's, was classified for over 
sixty years as a "degenerative disorder" of the 
central nervous system (CNS). 
Approximately five years ago, however, it was 
shown that the disorder is due to the deficient 
activity of an enzyme, hexosaminidase A, which 
catabolizes a normally occurring ganglioside. The 
accumulation of this sphingolipid causes progressive 
CNS deterioration in an infant who previously de-
veloped normally for the first six-to-nine months 
of life. Death by the age of four or five is inevitable 
since no cure is available or imminent. 
Over the past few years, an accurate procedure 
for the quantitation of hexosaminidase A (hex A) 
activity in serum has been developed whioh identifies 
the carriers of this autosomal recessive disorder. 
Because the Tay-Sachs disease occurs one hundred 
times as frequently in Ashkenazi Jews (those Jews 
of Eastern European and Russian ancestry who 
represent 90% of the United States Jews) as com-
pared to Gentiles and Sephardic Jews, it has become 
feasible and advisable to use this test to screen this 
population for the carrier state. Identification of 
the carrier is important for the following reasons: 
1) It alerts relatives of carriers (through ap-
propriate genetic counseling) of their very 
high- risk for also being a carrier; 
2) It allows identification of couples in the 
childbearing age who may both have the 
abnormal gene and are therefore at a 1 : 4 
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risk for having a Tay-Sachs infant. If both 
members of a parent pair are carriers, 
three alternatives exist: 
a) limitation of family size; 
b) therapeutic termination of an involved fetus 
diagnosed by amniocentesis in the 4th 
month of pregnancy; 
c) artificial insemination from a male known 
not to be a Tay-Sachs carrier-this ap-
proach would only be suggested where 
amniocentesis or termination of pregnancy 
are not acceptable to the parents. 
Over the past twenty months, the Departments 
of Pediatrics and Pathology at MCV, in cooperation 
with the Virginia State Health Department and 
concerned local physicians and volunteers, have 
organized intensive educational campaigns to out-
line the rationale of Tay-Sachs carrier testing. These 
efforts in Richmond, Roanoke, Norfolk-Virginia 
Beach, Hampton-Newport News, and Fredericks-
burg, have yielded a voluntary turnout of over 3600 
adult Jews at designated testing dates in community 
centers. 
Complete analysis of over 2000 specimens 
has thus far disclosed a carrier incidence of 1: 30. 
This figure is in close agreement with the 1 : 28 
figure found by the first and largest "outreach" 
Tay-Sachs screening program-that developed by 
Dr. Michael Kaback of the Johns Hopkins Uni-
versity Medical Center for the Baltimore-Wash-
ington area. Approximately a dozen other large 
cities have launched similar programs, but none 
has surpassed the Virginia experience in providing 
this testing to so many people over so large an area. 
Of equal importance to education and testing 
in such a detection program is the availability of 
adequate counseling for the carrier. Professional 
genetic counselors have provided this service for 
every Tay-Sachs carrier in Virginia, including advice 
concerning the importance and method of testing 
at-risk relatives. 
The ultimate national goal of such a carrier 
detection program is to avert the birth of Tay-
Sachs children. This could be done most efficiently 
by testing only married Jewish couples in the 
child-bearing age prior to their planning any chil-
dren. Because lack of funds and the complexity of 
the enzyme measurement presently prohibit the 
wide spread availability of the test, however, this 
is not feasible in most areas of the country. Logic 
dictates, therefore, that the best alternative is first 
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to identify which families (in cities where the test 
is available) carry the gene abnormality and then 
to urge testing for high-risk relatives residing in 
smaller cities where screening is not available. The 
MCV Tay-Sachs Screening Program has received 
frozen serum from as distant a city as Niagara 
Falls, New York, where the relative of a Richmond 
carrier resided. 
For further information regarding the MCV 
Tay-Sachs Screening Program, contact either Dr. 
Peter Mamunes or Dr. Seymour Bakerman by 
writing to Box 187, Medical College of Virginia, 
Richmond 23298, or by telephoning 804-770-3033. 
Sickle cell disease differs from Tay-Sachs dis-
ease in many ways. From the standpoint of carrier 
detection programs, however, the most important 
differences are that: 
1) The test is much simpler and blood speci-
mens can be mailed into a central labor-
atory; 
2) The carrier rate is considerably higher-
approximately 1: 12; 
3) No prenatal test is available when both 
parents are known carriers. 
For these reasons, a greater effort of education and 
testing at an earlier age are indicated. 
Much of the screening for sickle cell trait in 
in the state of Virginia is accomplished by the 
Virginia Sickle Cell Anemia Awareness Program 
(VaSCAP) of the Medical College of Virginia, and 
the sickle cell program of the State Health Depart-
ment. The purposes of these programs are to edu-
cate the public, to provide a screening for young 
people who wish to know whether they carry the 
recessive trait for sickling, and to provide counseling 
for those who have been tested. 
The VaSCAP program at the Medical College 
of Virginia tests young people in the child-bearing 
age, as well as premarital blood samples when 
the test is desired. A total of 11,000 specimens 
per year have been screened, many of them from 
the Richmond metropolitan area. The laboratory 
of the Stat0 Health Department has a capacity for 
up to 40,000 tests a year and collects samples from 
all over the state from individuals of any age. 
The VaSCAP program at MCV also provides 
educational services for the school systems in greater 
Richmond and other outlying areas, as well as edu-
cational programs for organizations and health 
clinics where it is requested. Screening programs 
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are provided for public schools and colleges in the 
area, and counseling programs are offered for indi-
viduals tested in the program. In addition, the 
VaSCAP program has provided a series of seminars 
for public health nurses throughout the state to 
teach a larger number of individuals the principles 
of counseling for sickle cell trait. 
The offices of the Virginia Sickle Cell Anemia 
Awareness Program are at 1008 East Clay Street, 
Richmond, Virginia 23298, and the program is 
supervised by Mrs. Florence Cooper. The telephone 
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number is 770-7797. The program of the State 
Health Department is directed by Dr. Patricia Hunt, 
Director, Bureau of Child Health, with offices in 
the Madison Building in Richmond. 
Carrier detection programs, such as those above 
described, have proven that the public will volun-
tarily present themselves for testing if there is ap-
propriate precedent education and follow-up coun-
seling. Every physician should acquaint himself with 
these recently available services and join the effort 
to reduce the incidence of these dreadful disorders. 
